|
 |
|
Alan Shaw Ph.D.
Chief Executive Officer
Dr. Shaw joined VaxInnate from the Merck Vaccine Research Division where he was Executive Director of MVD's Public Policy, Public Health and Medical Affairs Department.
|
|
|
Thomas Hofstaetter, PhD
President and Chief Operating Officer
Prior to
joining
VaxInnate,
Dr.
Hofstaetter
spent
more
than 30
years in
leadership
positions
at
research-based
pharmaceutical
companies.
|
|
|
Andrew Drechsler
Chief Financial Officer
Andrew Drechsler joined VaxInnate in June 2007, from Valera Pharmaceuticals, Inc. where he served as Chief Financial Officer.
|
|
|
David Taylor MD
Chief Medical Officer
Dr. Taylor, Chief Medical Officer, joined VaxInnate in March 2007 from Salix Pharmaceuticals, where he served as Chief Medical Officer and VP, Medical Affairs.
|
|
|
Robert Becker Ph.D. MBA
VP Business Development
Dr. Becker joined VaxInnate in December 2005 with 15 years of vaccine development and industry experience at Sanofi Pasteur, leaving as a VP of Corporate Development.
|
|
|
Lynda Tussey, Ph.D.
VP
Research
&
Development
Dr. Tussey joined VaxInnate in 2004 from Purdue Pharma where, as Program Leader of Immunotherapeutics , she led the overall development of cancer vaccine program.
|
|
|
| |
|
|
|
|
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza.
The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy.
|
VaxInnate was founded by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity.
The company started in 2002 with a research team in New Haven, CT. In 2004, the company expanded and established a development team and corporate headquarters in Cranbury, NJ.
|
VaxInnate seeks to develop, manufacture and commercialize its products on a global basis through collaborative, open relationships with its partners.
To explore business opportunities with VaxInnate, please contact Business Development.
Robert S. Becker
Vice President, Business Development
Telephone: +1 609 860 2277
E-mail:
Bob.Becker@vaxinnate.com
|
|
|
